A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in headache burden over 12 weeks in people with episodic migraine, despite a transient improvement with the 1 mg dose at week 4. Exploratory analyses suggested that smoking and sex may influence tizanidine exposure, while sex-specific efficacy signals remained hypothesis-generating and require confirmation.
